Clinical Trial Update: Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for alpelisib in participants with transorally resectable HPV-associated stage I-IVA oropharyngeal squamous cell carcinoma (CDKN2A-p16 posi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oropharyngeal Squamous Cell Carcinoma

Drugs mentioned

• Alpelisib (alpelisib)

Snippet

Sponsor: University of Arizona | Conditions: CDKN2A-p16 Positive, HPV Positive Oropharyngeal Squamous Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2024-04-17